18F-FDG PET/CT锁骨上淋巴结摄取对临床N3c局部晚期乳腺癌的预后价值
多因素分析显示SUVR-肿瘤>3.26与SUVR-锁骨上淋巴结>1.05为总生存的预后因素,两者均高者5年OS率仅51.0%。
要点
- SUVR-肿瘤>3.26与SUVR-锁骨上淋巴结>1.05均为OS的独立预后因素。
- 两者均高的患者5年OS率51.0%,显著劣于仅一项高或均不高者。
- 本研究未发现对无病生存有预后意义的临床病理或PET/CT参数。
核心结论
- 除肿瘤SUVR外,锁骨上淋巴结SUVR似有助于识别预后最差的cN3c乳腺癌患者。
研究设计与样本
- 以肝脏SUVmean归一化获得SUVR-肿瘤、SUVR-腋窝淋巴结和SUVR-锁骨上淋巴结。
- 采用Cox比例风险模型预测DFS和OS,并用Kaplan-Meier分析评估组间差异。
主要发现
- 中位随访70.0个月(范围6-128个月)期间,23例(41.8%)复发,13例(23.6%)死亡。
- 多因素分析中,SUVR-肿瘤>3.26与OS相关(HR 7.26;95%CI 1.58-33.31;P=0.01)。
- SUVR-锁骨上淋巴结>1.05与OS相关(HR 8.47;95%CI 1.09-65.87;P=0.04)。
- 未发现对DFS有预后意义的临床病理或PET/CT参数。
- 5年OS率:组1(SUVR-肿瘤≤3.26且SUVR-锁骨上淋巴结≤1.05,n=11)为100%,组2(任一>阈值,n=27)为85.2%,组3(两者均>阈值,n=17)为51.0%;组3劣于组1(P<0.01)和组2(P<0.01)。
关键数值与推荐
- SUVR-肿瘤阈值3.26,SUVR-锁骨上淋巴结阈值1.05,用于OS风险分层。
- 按两阈值将患者分为3组:组1均≤阈值,组2任一>阈值,组3均>阈值。
临床怎么用
- 对cN3c乳腺癌患者,可计算肿瘤与锁骨上淋巴结SUVR进行OS风险分层。
- 两者SUVR均高于阈值者预后最差,或需更密切随访或强化治疗评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We investigated the prognostic value of F-FDG uptake in the supraclavicular lymph node (SCLN) on PET/CT in breast cancer patients with clinical ipsilateral SCLN metastasis (cN3c). METHODS: Fifty-five female patients with initial F-FDG PET/CT were treated with curative intent. For semiquantitative analysis, the SUVmax of the primary tumor, axillary lymph node, and SCLN were normalized by the SUVmean of the liver (defined as SUVR-tumor, SUVR-axillary lymph node, and SUVR-SCLN, respectively). Cox proportional hazards models were used to predict disease-free survival (DFS) and overall survival (OS). Differences in DFS and OS were assessed by Kaplan-Meier analysis. RESULTS: Twenty-three patients (41.8%) experienced recurrence, and 13 (23.6%) died during follow-up (median, 70.0 months; range, 6-128 months). In multivariate analysis, SUVR-tumor greater than 3.26 (hazards ratio, 7.26; 95% confidence interval, 1.58-33.31; P = 0.01) and SUVR-SCLN greater than 1.05 (hazards ratio, 8.47; 95% confidence interval, 1.09-65.87; P = 0.04) were prognostic for OS. No clinicopathologic or PET/CT parameters were prognostic for DFS. The patients were divided into 3 groups: group 1 (n = 11, SUVR-tumor ≤3.26 and SUVR-SCLN ≤1.05); group 2 (n = 27, SUVR-tumor >3.26 or SUVR-SCLN >1.05); and group 3 (n = 17, SUVR-tumor >3.26 and SUVR-SCLN >1.05). The 5-year OS rates were 100% in group 1, 85.2% in group 2, and 51.0% in group 3. Group 3 showed worse prognosis than group 1 (P < 0.01) and group 2 (P < 0.01). CONCLUSIONS: In addition to SUVR-tumor, SUVR-SCLN seemed to play an important role in selecting patients with the worst prognosis.
引用
- Lee SH, Kim SH, Park HS, et al. The Prognostic Value of 18F-FDG Uptake in the Supraclavicular Lymph Node (N3c) on PET/CT in Patients With Locally Advanced Breast Cancer With Clinical N3c. Clin Nucl Med. 2019. PMID: 30540598. doi:10.1097/RLU.0000000000002365
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。